Matching articles for "tezacaftor"
Issue 1725 · March 31, 2025 Free
Correction

In our recent article on the combination of vanzacaftor, tezacaftor, and deutivacaftor (Alyftrek) for cystic fibrosis (Med Lett Drugs Ther 2025; 67:41), Table 3 misstated the formulations and dosage of the…

Med Lett Drugs Ther. 2025 Mar 31; 67(1725):56 doi:10.58347/tml.2025.1725d
In our recent article on the combination of vanzacaftor, tezacaftor, and deutivacaftor (Alyftrek) for cystic fibrosis (Med Lett Drugs Ther 2025; 67:41), Table 3 misstated the formulations and dosage of the combination of elexacaftor, tezacaftor, and ivacaftor (Trikafta).
Issue 1724 · March 17, 2025
Vanzacaftor, Tezacaftor, and Deutivacaftor (Alyftrek) for Cystic Fibrosis

The FDA has approved Alyftrek (Vertex) , an oral fixed-dose combination of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators vanzacaftor, tezacaftor, and deutivacaftor, for once-daily…

Med Lett Drugs Ther. 2025 Mar 17; 67(1724):41-3 doi:10.58347/tml.2025.1724a
The FDA has approved Alyftrek (Vertex) , an oral fixed-dose combination of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators vanzacaftor, tezacaftor, and deutivacaftor, for once-daily treatment of cystic fibrosis (CF) in patients ≥6 years old who have at least one F508del mutation or another responsive mutation in the CFTR gene. This is the first approval for vanzacaftor and for deutivacaftor, a deuterated form of ivacaftor. Trikafta , a twice-daily oral fixed-dose combination of elexacaftor, tezacaftor, and ivacaftor, is FDA-approved for the same indication in patients ≥2 years old.
Issue 1589 · January 13, 2020
Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) for Cystic Fibrosis

The FDA has approved Trikafta (Vertex), a fixed-dose combination of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators elexacaftor, tezacaftor, and ivacaftor, for oral treatment of…

Med Lett Drugs Ther. 2020 Jan 13; 62(1589):5-7
The FDA has approved Trikafta (Vertex), a fixed-dose combination of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators elexacaftor, tezacaftor, and ivacaftor, for oral treatment of cystic fibrosis (CF) in patients ≥12 years old who have at least one Phe508del mutation in the CFTR gene. About 90% of patients with CF have at least one copy of the Phe508del (also called F508del) mutation. This is the first approval for elexacaftor. Ivacaftor is available alone (Kalydeco) and in 2-drug combinations with tezacaftor (Symdeco) and lumacaftor (Orkambi) .
Issue 1558 · October 22, 2018
Tezacaftor/Ivacaftor (Symdeko) for Cystic Fibrosis

The FDA has approved the fixed-dose combination of tezacaftor and ivacaftor ( Symdeko – Vertex) for oral treatment of cystic fibrosis (CF) in patients ≥12 years old who are homozygous for the F508del (also…

Med Lett Drugs Ther. 2018 Oct 22; 60(1558):174-6
The FDA has approved the fixed-dose combination of tezacaftor and ivacaftor ( Symdeko – Vertex) for oral treatment of cystic fibrosis (CF) in patients ≥12 years old who are homozygous for the F508del (also called Phe508del or ΔF508) mutation or have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to the combination. About 50% of CF patients in the US are homozygous for the F508del mutation. This is the first approved indication for tezacaftor. Ivacaftor is also available in combination with lumacaftor as Orkambi for treatment of CF in F508del-homozygous patients ≥2 years old and alone as Kalydeco for treatment of CF in patients ≥12 months old with other sensitive mutations.